Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

LianBio Starts China Trials of SHP2 Inhibitor for NSCLC with EGFR Mutations

publication date: Aug 4, 2023

LianBio has dosed the first patient in a Phase I trial of BBP-398, an SHP2 inhibitor, in combination with AstraZeneca’s osimertinib, an epidermal growth factor receptor (EGFR) inhibitor. The trial will enroll non-small cell lung cancer (NSCLC) patients with EGFR mutations. In 2020, LianBio, a Shanghai-Princeton, NJ biotech, acquired China rights for two BridgeBio oncology assets, including BBP-398, in a $532 million agreement. BBP-398 is being developed for difficult-to-treat cancers. It was discovered in a collaboration between BridgeBio and The University of Texas MD Anderson Cancer Center. More details...

Stock Symbols: (NSDQ: LIAN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital